Effectiveness of nalbuphine, a κ-opioid receptor agonist and μ-opioid receptor antagonist, in the inhibition of INa, IK(M), and IK(erg) unlinked to interaction with opioid receptors

被引:11
|
作者
Liu, Yuan-Yuarn [1 ]
Hsiao, Hung-Tsung [2 ]
Wang, Jeffery C. -F. [2 ]
Liu, Yen-Chin [2 ]
Wu, Sheng-Nan [3 ,4 ]
机构
[1] Kaohsiung Vet Gen Hosp, Div Trauma, Dept Emergency, Kaohsiung, Taiwan
[2] Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Dept Anesthesiol, Tainan, Taiwan
[3] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan, Taiwan
[4] Natl Cheng Kung Univ, Coll Med, Dept Physiol, 1 Univ Rd, Tainan 70101, Taiwan
关键词
delayed-rectifier K+ current; erg-mediated K+ current; hippocampal neuron; M-type K+ current; nalbuphine; opioid receptor; voltage-gated Na+ current; CHANNELS; CELLS; TEFLUTHRIN; ACTIVATION; MORPHINE; ALPHA; STAGE;
D O I
10.1002/ddr.21568
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Nalbuphine (NAL) is recognized as a mixer with the kappa-opioid receptor agonist and the mu-opioid receptor antagonist. However, whether this drug causes any modifications in neuronal ionic currents is unclear. The effects of NAL on ionic currents in mHippoE-14 hippocampal neurons were investigated. In the whole-cell current recordings, NAL suppressed the peak amplitude of voltage-gated Na+ current (I-Na) with an IC50 value of 1.9 mu M. It shifted the steady-state inactivation curve of peak I-Na to the hyperpolarized potential, suggesting that there is the voltage dependence of NAL-mediated inhibition of peak I-Na. In continued presence of NAL, subsequent application of either dynorphin A(1-13) (1 mu M) or naloxone (30 mu M) failed to modify its suppression of peak I-Na. Tefluthrin (Tef; 10 mu M), a pyrethroid known to activate I-Na, increased peak I-Na with slowed current inactivation; however, further application of NAL suppressed Tef-mediated suppression of peak I-Na followed by an additional slowing of current inactivation. In addition, NAL suppressed the amplitude of M-type K+ current [I-K(M)] with an IC50 value of 5.7 mu M, while it slightly suppressed erg-mediated and delayed-rectifier K+ currents. In the inside-out current recordings, NAL failed to modify the activity of large-conductance Ca2+-activated K+ channels. In differentiated NG108-15 neuronal cells, NAL also suppressed the peak I-Na, and subsequent addition of Tef reversed NAL-induced suppression of I-Na. Our study highlights the evidence that in addition to modulate opioid receptors, NAL has the propensity to interfere with ionic currents including I-Na and I-K(M), thereby influencing the functional activities of central neurons.
引用
收藏
页码:846 / 856
页数:11
相关论文
共 50 条
  • [41] Synthesis and evaluation of 4-substituted piperidines and piperazines as balanced affinity μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands
    Bender, Aaron M.
    Clark, Mary J.
    Agius, Michael P.
    Traynor, John R.
    Mosberg, Henry I.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (02) : 548 - 551
  • [42] ANALGESIC POTENCY OF TRIMU-5 - A MIXED MU-2 OPIOID RECEPTOR AGONIST-MU-1-OPIOID RECEPTOR ANTAGONIST
    TIVE, LA
    PICK, CG
    PAUL, D
    ROQUES, BP
    GACEL, GA
    PASTERNAK, GW
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1992, 216 (02) : 249 - 255
  • [43] Navacaprant, a novel and selective kappa opioid receptor antagonist, has no agonist properties implicated in opioid-related abuse
    Morrison, Filomene G.
    Van Orden, Lori Jean
    Zeitz, Karla
    Kuijer, Eloise J.
    Smith, Sharon L.
    Heal, David J.
    Wallace, Tanya L.
    NEUROPHARMACOLOGY, 2024, 257
  • [44] AGONIST AND ANTAGONIST ACTIONS OF BUPRENORPHINE ON 3 TYPES OF OPIOID RECEPTOR IN ISOLATED PREPARATIONS
    KAJIWARA, M
    AOKI, K
    ISHII, K
    NUMATA, H
    MATSUMIYA, T
    OKA, T
    JAPANESE JOURNAL OF PHARMACOLOGY, 1986, 40 (01): : 95 - 101
  • [45] Synthesis of kappa opioid receptor agonist/antagonist chemotypes to treat drug addiction
    Taylor, William B.
    Slauson, Stephen
    Rane, Digamber
    Aube, Jeff
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 245
  • [46] Computational docking and opioidmimetics:: Investigation of δ-opioid agonist and antagonist receptor interactions.
    Bryant, S
    Lazarus, LH
    Salvadori, S
    Guerrini, R
    Balboni, G
    Jinsmaa, Y
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 226 : U461 - U461
  • [47] GR89,696 is a kappa-2 opioid receptor agonist and a kappa-1 opioid receptor antagonist in the guinea pig hippocampus
    Caudle, RM
    Mannes, AJ
    Iadarola, MJ
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1997, 283 (03): : 1342 - 1349
  • [48] Structure activity relationships of various N-substitutions on mixed-efficacy μ-opioid receptor (MOR) agonist/ δ-opioid receptor (DOR) antagonist peptidomimetics
    Harland, Aubrie
    Bender, Aaron
    Griggs, Nicholas
    Anand, Jess
    Jutkiewicz, Emily
    Traynor, John
    Mosberg, Henry
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250
  • [49] Risk of relapse to non-opioid addictive substances among opioid dependent patients treated with an opioid receptor antagonist or a partial agonist: A randomized clinical trial
    Opheim, Arild
    Benthc, Jurate Saltyte
    Solli, Kristin Klemmetsby
    Kloster, Pia S.
    Fadnes, Lars Thore
    Kunoe, Nikolaj
    Gaulen, Zhanna
    Tanum, Lars
    CONTEMPORARY CLINICAL TRIALS, 2023, 135
  • [50] PROPERTIES OF TAN-67, A NONPEPTIDIC DELTA-OPIOID RECEPTOR AGONIST, AT CLONED HUMAN DELTA-OPIOID AND MU-OPIOID RECEPTORS
    KNAPP, RJ
    LANDSMAN, R
    WAITE, S
    MALATYNSKA, E
    VARGA, E
    HAQ, W
    HRUBY, VJ
    ROESKE, WR
    NAGASE, H
    YAMAMURA, HI
    EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1995, 291 (02): : 129 - 134